Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Thalidomide-induced teratogenesis: history and mechanisms.

Vargesson N.

Birth Defects Res C Embryo Today. 2015 Jun;105(2):140-56. doi: 10.1002/bdrc.21096. Review.

2.

Thalidomide-a notorious sedative to a wonder anticancer drug.

Zhou S, Wang F, Hsieh TC, Wu JM, Wu E.

Curr Med Chem. 2013;20(33):4102-8. Review.

3.

A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.

Chen B, Restaino J, Norris L, Xirasagar S, Qureshi ZP, McKoy JM, Lopez IS, Trenery A, Murday A, Kahn A, Mattison DR, Ray P, Sartor O, Bennett CL.

J Oncol Pract. 2012 Nov;8(6):e158-67. doi: 10.1200/JOP.2011.000504.

4.

The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Rehman W, Arfons LM, Lazarus HM.

Ther Adv Hematol. 2011 Oct;2(5):291-308. doi: 10.1177/2040620711413165.

6.

Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease.

Saha S, Wald A.

Expert Opin Drug Saf. 2012 Nov;11(6):947-57. doi: 10.1517/14740338.2012.720970. Review.

7.

A phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response.

Vestermark LW, Holtved E, Dahlrot R, Brimnes MK, Svane IM, Bastholt L.

Ecancermedicalscience. 2008;2:91. doi: 10.3332/ecancer.2008.91.

8.

Treatment of cutaneous lupus.

Chang AY, Werth VP.

Curr Rheumatol Rep. 2011 Aug;13(4):300-7. doi: 10.1007/s11926-011-0180-z. Review.

9.

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.

Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S.

Am J Hematol. 2010 Oct;85(10):737-40. doi: 10.1002/ajh.21821.

10.

Treatment of multiple myeloma: a comprehensive review.

Kyle RA, Rajkumar SV.

Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88. doi: 10.3816/CLM.2009.n.056. Review.

11.
12.

Multiple myeloma.

Rajkumar SV.

Curr Probl Cancer. 2009 Jan-Feb;33(1):7-64. doi: 10.1016/j.currproblcancer.2009.01.001. Review. No abstract available.

13.
14.

Management of thalidomide toxicity.

Ghobrial IM, Rajkumar SV.

J Support Oncol. 2003 Sep-Oct;1(3):194-205. Review.

15.

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY.

Br J Cancer. 2003 Mar 24;88(6):822-7.

Supplemental Content

Support Center